Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
153.65B
Market cap153.65B
Price-Earnings ratio
19.89
Price-Earnings ratio19.89
Dividend yield
6.36%
Dividend yield6.36%
Average volume
61.63M
Average volume61.63M
High today
$27.08
High today$27.08
Low today
$27.01
Low today$27.01
Open price
$27.15
Open price$27.15
Volume
20.06K
Volume20.06K
52 Week high
$27.69
52 Week high$27.69
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 153.65B, Pfizer(PFE) trades at $27.08. The stock has a price-to-earnings ratio of 19.89 and currently yields dividends of 6.4%.

During the trading session on 2026-02-10, Pfizer(PFE) shares reached a daily high of $27.08 and a low of $27.01. At a current price of $27.08, the stock is +0.3% higher than the low and still 0.0% under the high.

Trading volume for Pfizer(PFE) stock has reached 20.06K, versus its average volume of 61.63M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

PFE News

Simply Wall St 13h
How Obesity Pipeline Gains And TrumpRx Move At Pfizer Have Changed Its Investment Story

In early February 2026, Pfizer reported mixed 2025 financial results, reaffirmed 2026 revenue guidance, highlighted progress in its GLP-1 obesity pipeline, secu...

How Obesity Pipeline Gains And TrumpRx Move At Pfizer Have Changed Its Investment Story
The Motley Fool 18h
Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend?

The stock has been fairly stable over the past year. Pfizer (PFE 0.70%) has been an underwhelming stock to own in recent years. Question marks about its growth...

Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend?
Simply Wall St 2d
Assessing Pfizer Valuation After New PF-3944 Obesity Trial Data And Market Reentry

Pfizer (PFE) is back in the obesity spotlight after reporting Phase 2b VESPER-3 data for its monthly GLP-1 injection, PF-3944, showing up to 12.3% placebo adjus...

Assessing Pfizer Valuation After New PF-3944 Obesity Trial Data And Market Reentry

Analyst ratings

57%

of 28 ratings
Buy
39.3%
Hold
57.1%
Sell
3.6%

More PFE News

Simply Wall St 3d
Is Pfizer Offering Value After Recent Share Price Rebound

If you are wondering whether Pfizer is genuinely good value or just looks cheap on the surface, this article walks through what the current numbers are really s...

Is Pfizer Offering Value After Recent Share Price Rebound
TipRanks 4d
Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults: What Investors Should Know

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer is running an early-stage clinical trial titled “An Interventional...

TipRanks 4d
Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Advances Mid-Stage Trial of New Obesity Drug PF-07976016 Study Overview: This Pha...

TipRanks 4d
H.C. Wainwright says Chantix news ‘significant win’ for Achieve Life Sciences

H.C. Wainwright views Pfizer’s (PFE) launch of Chantix among the 30 medicines it placed on the White House’s direct-to-consumer site, TrumpRx, as “a significant...

TipRanks 4d
Trump Trade: Argentina says U.S. to cut hundreds of tariffs

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump...

Seeking Alpha 4d
Pfizer wins FDA priority review for Hympavzi label expansion

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for it...

Pfizer wins FDA priority review for Hympavzi label expansion
TipRanks 4d
Pfizer says FDA grants Priority Review for sBLA for Hympavzi

Pfizer (PFE) announced that the U.S. FDA has accepted and granted Priority Review for the company’s supplemental Biologics License Application for Hympavzi to e...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.